Nuala Moran

Biologic drugs deliver health and wealth. But it is a long, fraught path from lab to bedside. Science|Business brought together research, business and policymakers to draft a risk-reduction plan for the new Parliament and Commission

Regrets, she has a few, but the real fault lies with politicians that remain tied to an analogue mind-set. The result is a two-speed Europe, says Neelie Kroes as she retires as Digital Commissioner – to be replaced by three men

The CEOs of Ablynx and uniQure, at a Science|Business event, tell their growth stories – and what Europe needs to do if there are to be more companies like theirs bringing new medicines to market

Leading entrepreneurs working to commercialise publicly-funded university research point to a lack of understanding of how IP should be shaped and protected to ensure commercial success.

Too great a focus on short-term innovation could damage the long-term ability to grow. New policies are needed to encourage longer cycle innovation and local production, says Hiram Samel of Oxford University’s Saїd Business School

Productivity in the pharma industry is up, but the origins of more than half of new drugs lies outside corporate labs.

Amendments to the European Data Protection regulation proposed in response to revelations of blanket electronic eavesdropping by the US must be dropped. If not, major international research projects in cancer, obesity and Alzheimer’s disease will come to a stop, say R&D funding bodies

Europe’s education institutions need to catch up in the digital learning stakes. But this requires more than beaming online courses into classrooms and lecture halls

Even for the most motivated entrepreneurs, it takes huge amounts of time and energy to commercialise leading-edge research. Change is needed to improve the framework for innovation, reducing risks and attracting patient investors